Anticancer therapeutic - Qubit Pharmaceuticals
Latest Information Update: 31 Mar 2025
At a glance
- Originator Qubit Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action KAT6A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 12 Mar 2025 Anticancer therapeutic - Qubit Pharmaceuticals is available for licensing as of 12 Mar 2025 (Qubit Pharmaceuticals pipeline, March 2025)
- 12 Mar 2025 Early research in Cancer in France (unspecified route) before March 2025 (Qubit Pharmaceuticals pipeline, March 2025)